Growth Hormone Therapy | Norditropin (somatropin) Injection

Selected Important Safety Information Do not use Norditropin if: you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing (respiratory) problems; you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea; you have cancer or other tumors; you are allergic to somatropin or any of the ingredients in Norditropin; your healthcare provider tells you that you have certain types of eye problems caused by diabetes (diabetic retinopathy); you are a child with closed bone growth plates (epiphyses). Indications and Usage What is Norditropin (somatropin) injection? Norditropin is a prescription medicine that contains human growth hormone and is used to treat: Important Safety Information (contd) Before taking Norditropin, tell your healthcare provider about all of your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

NZME Limited (NZX: NZM) Half Year Results to 30 June 2021 – sharechat.co.nz – sharechat

NZME Limited has today announced its financial results for the half year ended 30 June 2021, reporting Statutory Net Profit After Tax (NPAT) of $5.6 million, up 85% on the corresponding period in 2020. NZME also announced growth in Operating Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) to $30.1 million for the half year, representing 4% growth in Operating EBITDA against the first half of 2020

Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25 – Stockhouse

COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, August 25, 2021 at 4:30 p.m.

Study: Biosimilar rhGH Well Tolerated and Effective in Turner Syndrome – The Center for Biosimilars

A multicenter observational study of 348 children with Turner syndrome (TS) found that biosimilar recombinant human growth hormone (rhGH) therapy was safe and effective in real-life clinical practice. The investigators reported on a subgroup of patients with TS from the PAtients TReated with Omnitrope (PATRO) Children study, a long-term, postmarketing surveillance study of children treated with biosimilar rhGH (Omnitrope; Sandoz). TS is characterized by partial or complete loss of the second sex chromosome in females and is associated with comorbidities, including growth failure.